The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
RTOG 0436: A phase III trial evaluating the addition of cetuximab to paclitaxel, cisplatin, and radiation for patients with esophageal cancer treated without surgery.
David H. Ilson
Research Funding - Bristol-Myers Squibb
Jennifer Moughan
No relevant relationships to disclose
Mohan Suntharalingam
No relevant relationships to disclose
Adam Dicker
No relevant relationships to disclose
Lisa A. Kachnic
No relevant relationships to disclose
Andre A. Konski
No relevant relationships to disclose
Bapsi Chakravarthy
No relevant relationships to disclose
Chris Anker
No relevant relationships to disclose
Harish V. Thakrar
No relevant relationships to disclose
Naomi Horiba
No relevant relationships to disclose
Vivek Kavadi
No relevant relationships to disclose
Melvin Deutsch
No relevant relationships to disclose
Adam Raben
No relevant relationships to disclose
Kevin S. Roof
No relevant relationships to disclose
John H. Suh
No relevant relationships to disclose
Jondavid Pollock
No relevant relationships to disclose
Howard Safran
No relevant relationships to disclose
Christopher H. Crane
No relevant relationships to disclose